Arix Bioscience PLC - London-based life sciences focused investor - Portfolio company LogicBio Therapeutics Inc announced the clinical trial design for the planned phase 1/2 clinical trial of its LB-001 programme in paediatric patients with methylmalonic acidemia, a disorder in which the body cannot break down certain proteins and fats. This trial follows investigational new drug application clearance from the US Food & Drug Administration. LogicBio expects patient enrolment to begin in early 2021.
Current stock price: 81.20 pence
Year-to-date change: down 24%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.